Stella J. Bowcock - Publications

SECURE study: baseline findings from a UK prospective cohort of incidentally detected MGUS.

Journal: Blood cancer journal

Published: January 15, 2026

Incidence of first and subsequent fractures in multiple myeloma patients: a parallel cohort study using UK CPRD dataset.

Journal: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Published: September 09, 2025

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.

Journal: British journal of haematology

Published: August 08, 2025

SECURE study: Incidentally detected MGUS patients have comparable depression and anxiety rates to UK general population.

Journal: British journal of haematology

Published: July 26, 2025

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Journal: Haematologica

Published: September 17, 2023

Patient-reported symptoms and diagnostic journey in Multiple Myeloma.

Journal: Frontiers in oncology

Published: August 24, 2023

Determinants of durable humoral and T cell immunity in myeloma patients following COVID-19 vaccination.

Journal: European journal of haematology

Published: July 23, 2023

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.

Journal: Cancers

Published: February 28, 2023

An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United Kingdom.

Journal: Value in health regional issues

Published: August 12, 2022

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial.

Journal: BMJ open

Published: June 02, 2022

Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T-cell response.

Journal: British journal of haematology

Published: November 10, 2021

COVID symptoms, testing, shielding impact on patient-reported outcomes and early vaccine responses in individuals with multiple myeloma.

Journal: British journal of haematology

Published: August 03, 2021